No Data
U.S. stock movement | BEIGENE (ONC.US) pre-market rose over 3% as Toripalimab was approved for a new indication in the U.S.
On Tuesday, BEIGENE (ONC.US) rose over 3% in Pre-Market Trading, priced at $253.98.
BeiGene Shares Are Trading Higher After the Company Announced FDA Approval of Tevimbra/chemotherapy Combination.
BeiGene Says FDA Approves Tevimbra for Esophageal Cancer First-Line Treatment
Express News | FDA Approves TEVIMBRA In US For The First-Line Treatment Of Adults With Unresectable Or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
Express News | Tevimbra Approved in U.S. for First-Line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination With Chemotherapy
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination With Chemotherapy
